ArticleRheumatology advances in practice2025
Identifying axial spondyloarthritis flares using the Evaluation of Ankylosing Spondylitis Quality of Life (EASiQoL) patient-reported outcome measure via an online portal: the FASTER study protocol.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: People with axial spondyloarthritis (axSpA) frequently experience increases in symptoms (flares) related to pain, stiffness and fatigue. Despite frequent use of the term 'flare' within axSpA, it is poorly defined and characterised. No widely accepted patient-reported outcome measure (PROM) exists that can identify axSpA flares or quantify their severity. However, the Evaluation of Ankylosing Spondylitis Quality of Life (EASiQoL) is a patient-derived axSpA-specific PROM with strong evidence of its ability to assess quality of life, an aspect affected by changes in symptoms. Objective: This study will look at the feasibility of identifying flares in people with axSpA through regular completion of an electronic (e) version of the EASiQoL. Methods: We will conduct a mixed-methods 12-month prospective cohort study. Up to 1000 people with axSpA from rheumatology departments and all members of the National Axial Spondyloarthritis Society will be invited to complete a baseline questionnaire containing several ePROMs, including the EASiQoL, via a bespoke online study portal. Of the estimated 1280 responders, all will receive e-mail reminders to complete monthly questionnaires for the following 10 months and a final 12-month follow-up questionnaire. Over the 12 months, a subsample of up to 40 participants who report a flare during this period will be invited to a qualitative interview. Their lived experience of 'flare' and how this was reflected in their EASiQoL scores will be explored. Potential impact: Collection of ePROM data sensitive to the presence of axSpA flares should provide readily accessible information to both patients and rheumatology teams to monitor disease course and develop more effective flare pathways in axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.